Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease

(2014) Marianne R. Smith et al.   HUMAN MOLECULAR GENETICS

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study

(2014) Victoria Gonzalez et al.   JOURNAL OF NEUROSURGERY

HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease1,2,3

(2014) Julie C. Stout et al.   MOVEMENT DISORDERS

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Huntington disease: natural history, biomarkers and prospects for therapeutics

(2014) Christopher A. Ross et al.   Nature Reviews Neurology

PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease

(2014) H. D. Rosas et al.   NEUROLOGY

Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington's Disease

(2014) Liliana B. Menalled et al.   PLoS One

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Cysteamine: an old drug with new potential

(2013) Martine Besouw et al.   DRUG DISCOVERY TODAY

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

(2013) Timothy M Miller et al.   LANCET NEUROLOGY

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

(2013) Sarah J Tabrizi et al.   LANCET NEUROLOGY

The pridopidine paradox in Huntington's disease

(2013) Ralf Reilmann   MOVEMENT DISORDERS

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

(2013)   MOVEMENT DISORDERS

A 5-year follow-up of deep brain stimulation in Huntington's disease

(2013) Jose Luis López-Sendón Moreno et al.   PARKINSONISM & RELATED DISORDERS

Q02 A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients

(2012) SD Süssmuth et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cognitive domains that predict time to diagnosis in prodromal Huntington disease

(2012) Deborah Lynn Harrington et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease

(2012) Julie C Stout et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Longitudinal Evaluation of Neuropsychiatric Symptoms in Huntington's Disease

(2012) Jennifer C. Thompson et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study

(2012) E. Ray Dorsey et al.   PLoS One

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

(2011) Paul Morgan et al.   DRUG DISCOVERY TODAY

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

(2011) Justo Garcia de Yebenes et al.   LANCET NEUROLOGY

An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers

(2011) Anthony L. Vaccarino et al.   MOVEMENT DISORDERS

Pharmacologic approaches to the treatment of Huntington's disease

(2011) Charles S. Venuto et al.   MOVEMENT DISORDERS

Assessment of involuntary choreatic movements in Huntington's disease-Toward objective and quantitative measures

(2011) Ralf Reilmann et al.   MOVEMENT DISORDERS

Benefits, challenges and obstacles of adaptive clinical trial designs

(2011) Shein-Chung Chow et al.   Orphanet Journal of Rare Diseases

Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington's Disease

(2010) R. J. Kleiman et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

(2010) Sarah J Tabrizi et al.   LANCET NEUROLOGY

Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease

(2010) Ralf Reilmann et al.   MOVEMENT DISORDERS

Grasping premanifest Huntington's disease - shaping new endpoints for new trials

(2010) Ralf Reilmann et al.   MOVEMENT DISORDERS

Tapping linked to function and structure in premanifest and symptomatic Huntington disease

(2010) N. Bechtel et al.   NEUROLOGY

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases

(2010) C. Gibrat et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

(2009) Sarah J Tabrizi et al.   LANCET NEUROLOGY